Table 5. Anatomic Stage/Prognostic Groupsab
| Group | T | N | M | PSA | Gleason |
| I | T1a–c | N0 | M0 | PSA <10 | Gleason ≤6 |
| T2a | N0 | M0 | PSA <10 | Gleason ≤6 |
| T1–2a | N0 | M0 | PSA X | Gleason X |
| IIA | T1a–c | N0 | M0 | PSA <20 | Gleason 7 |
| T1a–c | N0 | M0 | PSA ≥10 <20 | Gleason ≤6 |
| T2a | N0 | M0 | PSA ≥10 <20 | Gleason ≤6 |
| T2a | N0 | M0 | PSA <20 | Gleason 7 |
| T2b | N0 | M0 | PSA <20 | Gleason ≤7 |
| T2b | N0 | M0 | PSA X | Gleason X |
| IIB | T2c | N0 | M0 | Any PSA | Any Gleason |
| T1–2 | N0 | M0 | PSA ≥20 | Any Gleason |
| T1–2 | N0 | M0 | Any PSA | Gleason ≥8 |
| III | T3a–b | N0 | M0 | Any PSA | Any Gleason |
| IV | T4 | N0 | M0 | Any PSA | Any Gleason |
| Any T | N1 | M0 | Any PSA | Any Gleason |
| Any T | Any N | M1 | Any PSA | Any Gleason |
| PSA = prostate-specific antigen. |
| aReprinted with permission from AJCC: Prostate. In: Edge SB, Byrd DR, Compton CC, et al., eds.: AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer, 2010, pp 457-68. |
| bWhen either PSA or Gleason is not available, grouping should be determined by T stage and/or either PSA or Gleason as available. |
